Nuvation Bio Inc. Deferred State and Local Income Tax Expense (Benefit)
Nuvation Bio Inc. (NUVB) reported Deferred State and Local Income Tax Expense (Benefit) of -$213.31 thousand for the 8-month period ending 2020-12-31, per its 10-K/A filed 2021-05-21.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2021-05-21
- 2020-12-31: Deferred State and Local Income Tax Expense (Benefit) 8 month -$213.31K; Deferred State and Local Income Tax Expense (Benefit) 8 month as first filed -$270.01K.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 8 month | Deferred State and Local Income Tax Expense (Benefit) 8 month as first filed |
|---|---|---|
| 2020-12-31 | -$213.31K 10-K/A · filed 2021-05-21 | -$270.01K 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |